Forest Takes "Wait And See" Approach On Effect Of Antidepressant "Black Box" Labeling
This article was originally published in The Pink Sheet Daily
Executive Summary
The company does not anticipate a "dramatic disruption" to the marketplace since the safety issues have been widely publicized, COO Goodman says. He suggests that the effect on Lexapro sales could mirror the temporary dip seen when the safety issues first surfaced last summer.